Skip to main navigation

Investor Relations

March 03, 2021

Abivax publishes data of ABX464 induction and long-term maintenance phase 2a ulcerative colitis study in the prestigious journal “Gastroenterology"

March 01, 2021

Abivax appoints Dr Sophie Biguenet as Chief Medical Officer

January 05, 2021

Abivax publishes review in Drug Discovery Today on mechanism of action and transformative potential of ABX464 as therapy for inflammatory diseases

December 22, 2020

Abivax’s Covid-19 phase 2b/3 miR-AGE trial with ABX464 declared Research National Priority by the French government’s clinical trial council

December 21, 2020

Abivax to present at the 39th Annual J.P. Morgan Healthcare Conference ahead of major clinical milestones